Canopy Growth Corp

Annual Trend FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 FY 2026 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net loss ($7.6m) ($54.1m) ($670.1m)
Net Income (Loss) Attributable to Parent ($1.3b)
($1.7b) -32.06%
($302.2m) +82.68%
($3.3b) -984.83%
($657.3m) +79.95%
($598.1m) +9.00%
($262.9m) +56.04%
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest ($54.1m) ($670.1m) ($1.4b) ($1.7b) ($320.5m) ($3.3b) ($675.8m) ($598.1m) ($262.9m)
Net Income (Loss) Attributable to Noncontrolling Interest ($66.1m) $74.1m ($18.3m) ($31.4m)
Depreciation $73.7m $70.9m $76.2m $56.7m $28.4m $21.5m $19.0m $19.6m
Amortization of Intangible Assets $1.9m $11.8m $16.9m $51.3m $56.2m $38.2m $27.8m $24.8m $21.6m $17.4m
Depreciation of property, plant and equipment $4.1m $8.7m $30.1m $36.8m
Deferred Income Tax Expense (Benefit) ($2.7m) $1.6m $12.3m ($138.3m) ($34.5m) ($6.6m) ($667k) $12.1m $6.8m $36k ($397k)
Share-based Payment Arrangement, Noncash Expense $320.3m $91.1m $47.5m $31.2m $14.2m ($4.2m) $4.3m $5.7m
Adjustments For Share-Based Payments $51.2m $287.8m
Share-based Payment Arrangement, Expense $62.2m $8.1m $5.7m
Share-based compensation $10.0m $51.2m $287.8m $5.7m
Equity Method Investment, Other than Temporary Impairment $55.2m
Gain (Loss) on Sale of Assets and Asset Impairment Charges ($66.0m) ($31.2m) ($67.1m)
Goodwill, Impairment Loss $40.7m $1.8b $42.1m $47.5m $58.1m
Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill) $8.0m
Restructuring Costs and Asset Impairment Charges $623.3m $534.4m $369.3m $2.3b $67.1m
Income (Loss) from Equity Method Investments $50k $1.5m $10.8m ($64.4m) ($52.6m) ($100k)
Other Nonoperating Income (Expense) $224.3m ($387.9m) $753.3m ($466.0m) ($242.6m) ($479.9m) ($101.2m)
Share of loss on equity investments $50k $1.5m $10.8m
Investments in equity method investees ($26.2m) ($36.9m)
Changes in operating assets and liabilities:
Increase (Decrease) in Accounts Receivable ($21.0m) $12.0m ($3.7m) $9.9m $3.7m $4.5m ($25.7m) $16.6m
Increase (Decrease) in Inventories $177.1m ($17.2m) ($173.2m) ($55.6m) ($1.0m) $17.7m ($3.7m) $4.3m
Inventory Write-down $169.3m $79.9m $237.1m $82.8m $9.4m $10.3m $17.0m
Fair value changes in biological assets included in inventory sold and other charges $35.0m $66.3m $129.5m
Other assets ($1.9m) ($19.4m)
Other liabilities $0 $54.3m
Net Cash Provided by (Used in) Operating Activities ($27.1m)
($81.5m) -200.84%
($520.5m) -538.62%
($772.6m) -48.44%
($465.7m) +39.72%
($545.8m) -17.19%
($557.5m) -2.15%
($281.9m) +49.43%
($165.8m) +41.21%
($63.8m) +61.50%
($78.5m) -23.00%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment ($29.4m) ($176.0m) ($644.5m) $704.9m $164.5m $36.7m $9.2m $3.4m $10.8m $5.3m ($5.2m)
Proceeds From Sales Of Property Plant And Equipment Classified As Investing Activities $37k $75k
Purchases of marketable securities ($118k) ($2.0b)
Investments in other financial assets ($22.4m) ($91.3m)
Payments for (Proceeds from) Other Investing Activities $18.1m ($4.2m) $7.7m ($7.0m)
Net Cash Provided by (Used in) Investing Activities ($18.6m) ($223.6m) ($3.2b) ($347.7m) ($884.1m) $230.8m $433.4m $241.6m ($47.8m) ($21.3m) ($21.4m)
Cash flows from financing activities:
Repayments of Long-term Debt $115.0m $15.6m $50.8m $118.2m $509.8m $100.0m $221.5m ($220.6m)
Proceeds from Issuance of Long-term Debt $3.5m $600.0m $14.8m $893.2m $0 $135.2m $68.3m $208.0m $208.0m
Repayment of long-term debt ($959k) ($1.2m) ($4.7m)
Proceeds from Issuance of Common Stock $130.3m $470.7m $50.0m $335.9m
Proceeds from (Payments for) Other Financing Activities ($3.0m) ($38.0m) ($36.3m) ($24.5m) ($17.2m)
Net Cash Provided by (Used in) Financing Activities $132.1m
$525.8m +298.07%
$5.8b +1010.05%
($57.2m) -100.98%
$1.3b +2312.64%
($45.5m) -103.60%
($19.7m) +56.75%
($465.1m) -2261.40%
$148.7m +131.97%
$332.4m +123.60%
$299.5m -9.91%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $69.6m ($1.2b) ($148.5m) ($378.6m) ($99.0m) ($506.7m) ($56.5m) $250.9m $325.8m
Cash and cash equivalents, beginning of period $101.8m $322.6m $2.5b
Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $69.6m ($204k) ($63.5m) ($18.1m) $44.9m ($1.3m) $8.4m $3.6m $10.8m
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Proceeds from Stock Options Exercised $7.0m $11.1m $48.2m $41.4m $156.9m $5.6m $281k $112k $0
Supplemental disclosure of cash flow information:
Interest Paid, Excluding Capitalized Interest, Operating Activities $119.2m $131.8m $98.1m $64.9m $29.0m
Income Taxes Paid, Net $5.5m $144k
Additional Financial Items
Adjustments For Decrease Increase In Trade Account Receivable ($15.7m) ($67.7m)
Adjustments For Increase Decrease In Trade Account Payable $27.1m $69.5m
Disposal Group, Not Discontinued Operation, Gain (Loss) on Disposal $16.1m
Foreign Currency Transaction Gain (Loss), Realized ($1.2m) ($18.0m) $5.4m ($8.5m) $704k $1.5m ($624k)
General And Administrative Expense $43.8m $168.4m
Goodwill $314.9m $1.5b $2.0b $1.9b $1.9b $85.6m $43.2m $46.0m $55.7m $58.1m
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($483.7m) ($604.1m) ($262.9m)
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($192.1m) $6.0m $0
Income Tax Expense (Benefit) ($2.7m) $1.6m $12.3m ($121.6m) ($13.1m) ($8.9m) ($4.8m) $12.3m $7.1m $23k
Increase Decrease In Working Capital $28.5m $262.2m $5.8m
Interest Paid Classified As Financing Activities $14.5m
Operating Expenses $1.6b $1.3b $889.6m $2.7b $309.6m $196.7m $231.3m
Purchase Of Intangible Assets Classified As Investing Activities $2.1m $38.3m
Revenue from Contract with Customer, Including Assessed Tax $439.6m $607.2m $582.2m $450.9m $343.9m $314.0m $346.8m
Unrealized gain on changes in fair value of biological assets ($49.1m) ($100.3m) ($167.6m)
Other income and expense ($5.7m) ($38.8m) $75.8m
Non-cash foreign currency ($201k) ($18.8m)
Purchases of intangible assets ($141k) ($2.1m) ($38.3m)
Net cash outflow on acquisition of subsidiaries $11.2m ($3.8m) ($380.5m)
Payment of share issue costs ($8.1m) ($10.0m) ($21.6m)
Proceeds from issuance of common shares and warrants $130.3m $470.7m $5.1b
Proceeds from issuance of shares by Canopy Rivers $54.9m $155.0m
Proceeds from exercise of stock options $7.0m $11.1m $48.2m
Proceeds from exercise of warrants $126k $770k $18.8m
Net cash inflow $86.4m $220.8m $2.2b

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.